Get the Stockscreener App
154.44
0.29%
0.45
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $154.44, with a volume of 2.76M.
It is up +0.29% in the last 24 hours and up +10.44% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$153.99
Open:
$153.52
24h Volume:
2.76M
Relative Volume:
1.12
Market Cap:
$36.86B
Revenue:
$222.29B
Net Income/Loss:
$1.56B
P/E Ratio:
24.09
EPS:
6.41
Net Cash Flow:
$2.44B
1W Performance:
+1.11%
1M Performance:
+10.44%
6M Performance:
+26.34%
1Y Performance:
+58.06%
1-Day Range:
$153.12
$155.28
1-Week Range:
$152.47
$155.28
52-Week Range:
$93.17
$156.44
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
154.44 | 36.46B | 222.29B | 1.56B | 2.44B | 6.41 |
|
MCK
Mckesson Corporation
|
719.51 | 89.51B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
291.24 | 56.66B | 310.23B | 1.69B | 3.58B | 8.62 |
|
HSIC
Henry Schein Inc
|
69.99 | 8.96B | 12.50B | 314.00M | 421.00M | 2.44 |
|
YI
111 Inc Adr
|
8.17 | 68.73M | 2.05B | -45.99M | 5.54M | -0.5634 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Continence Care Market Size to Surpass USD 9.54 Billion by 2031 With 5.6% CAGR, Surging Prevalence of Chronic Diseases Propels the Demand | The Insight Partners - GlobeNewswire Inc.
Interesting CAH Put And Call Options For July 11th - Nasdaq
Forget UnitedHealth. Cardinal Health Is the Best Healthcare Stock to Buy Right Now - 24/7 Wall St.
Nephron Research Adjusts Cardinal Health Price Target to $166 From $160 - marketscreener.com
Baird Adjusts Price Target on Cardinal Health to $181 From $170, Maintains Outperform Rating - marketscreener.com
Cardinal Health, Inc. (NYSE:CAH) is a favorite amongst institutional investors who own 89% - simplywall.st
Cardinal Health, Inc. (NYSE:CAH) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cardinal Health Stock: Is CAH Outperforming the Healthcare Sector? - MSN
FY2025 EPS Estimate for Cardinal Health Boosted by Analyst - Defense World
Cardinal Health ($CAH) Is Paying a $109M Settlement to Investors — Here’s How to Get Your Share - TradingView
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
Cardinal Health stock soars to all-time high of $155 By Investing.com - Investing.com South Africa
Cardinal Health stock soars to all-time high of $155 - Investing.com Australia
Jim Cramer On Cardinal Health (CAH) “They Are Impressive” - Insider Monkey
Jim Cramer On Cardinal Health (CAH) "They Are Impressive" - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail
CAH Q1 Earnings Call: Cardinal Health Misses Revenue Targets but Exceeds Profit Expectations Amid Tariff Headwinds - Yahoo Finance
Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Zacks Industry Outlook Highlights Cardinal Health, Labcorp and Align Technology - Yahoo Finance
Cardinal Health Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com
Cardinal Health Insiders Sold US$18m Of Shares Suggesting Hesitancy - Yahoo Finance
Cardinal Health (CAH) Faces Market Focus Amid Global Trade Talks - GuruFocus
Cardinal Health (CAH): Navigating Market Uncertainty | CAH Stock News - GuruFocus
JPMorgan Adjusts Cardinal Health Price Target to $156 From $145, Maintains Neutral Rating - marketscreener.com
Cardinal Health's (NYSE:CAH) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Cardinal Health (NYSE:CAH) Has Announced That It Will Be Increasing Its Dividend To $0.5107 - Yahoo Finance
Cardinal Health, Inc. (CAH): Among Billionaire Mason Hawkins’ Mid-Cap Stocks with Huge Upside Potential - Insider Monkey
-Charles River agrees with Elliott to add new directors, review business - marketscreener.com
Charles River to add new directors, review business in agreement with Elliott - marketscreener.com
Cardinal Health releases new report on the cell and gene therapy industry | CAH Stock News - GuruFocus
Cardinal Health releases new report on the cell and gene therapy industry - marketscreener.com
Cardinal Health releases new report on the cell and gene therapy industry – Company Announcement - Financial Times
Cardinal Health (NYSE:CAH) Announces Dividend Increase to US$1 Per Share - simplywall.st
Cardinal Health Board of Directors Approves Quarterly Dividend | - GuruFocus
Cardinal Health (CAH) Boosts Quarterly Dividend and Revises Earnings Guidance - GuruFocus
Cardinal Health Raises Dividend by About 1% - MarketWatch
Cardinal Health raises quarterly dividend to $0.5107 By Investing.com - Investing.com Canada
Cardinal Health Board of Directors Approves Quarterly Dividend - GuruFocus
Cardinal Health Increases Quarterly Dividend to $0.5107 a Share From $0.5056, Payable July 15 to Investors of Record July 1 - marketscreener.com
Cardinal Health Board of Directors Approves Quarterly Dividend | CAH Stock News - GuruFocus
Cardinal Health (CAH) Stock Target Price Increased by Morgan Stanley | CAH Stock News - GuruFocus
Argus Elevates Price Target for Cardinal Health (CAH) Amid Strat - GuruFocus
Are Investors Undervaluing Cardinal Health (CAH) Right Now? - Yahoo Finance
Cardinal Health (CAH) Price Target Increased by Morgan Stanley | - GuruFocus
Argus Adjusts Price Target on Cardinal Health to $162 From $148 - marketscreener.com
Cardinal Health’s Promising Growth Under New Leadership Justifies Buy Rating - TipRanks
Cardinal Health, Northrop Grumman Among 7 Companies To Announce Dividend Increases In First Half Of May - Seeking Alpha
Cardinal Health Third Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Cardinal Health (CAH): Analyst Raises Price Target Amid Strong P - GuruFocus
Cardinal Health (CAH): Analyst Raises Price Target Amid Strong Performance | CAH Stock News - GuruFocus
Cardinal Health Ups Forecast Again On Thriving Specialty Medicines - Finimize
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
2.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):